Navigation Links
FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
Date:8/25/2011

nal pain.  The median time to 50% reduction in symptoms for patients with cutaneous or abdominal attacks treated with FIRAZYR (n=43) compared to placebo (n=45) was 2.0 hours [95% CI 1.5, 3.0] versus 19.8 hours [95% CI 6.1, 26.3], respectively (p<0.001).  The median times to almost complete symptom relief were 8.0 versus 36.0 hours for FIRAZYR and placebo, respectively.  Additional rescue medications were used by 3 patients (7%) treated with FIRAZYR and 18 patients (40%) treated with placebo.  

FAST 1 and 2 included a total of 61 FIRAZYR-treated patients.  Across the three controlled trials, FIRAZYR had a median time to 50% reduction from baseline symptoms ranging from 2.0 to 2.3 hours.  

In an assessment of the first 5 FIRAZYR-treated attacks (621 doses for 582 attacks), the median times to a 50% reduction from the pretreatment composite 3-itemVAS score were similar across attacks (2.0, 2.0, 2.4, 2.0, 1.5 hours).  The majority (93%) of these attacks were treated with a single dose of FIRAZYR.

Among 60 patients with laryngeal attacks who were treated with FIRAZYR, efficacy results were similar to those observed for non-laryngeal sites of attack.

Self-administration of FIRAZYR by 56 patients was assessed in an open label trial.  Patients who administered FIRAZYR during an acute attack of HAE had a median time to 50% reduction from the pretreatment composite 3-item VAS score of 2.6 hours. The safety profile in these patients was similar to that of patients whose therapy was administered by healthcare professionals.

Important Safety Information

Because laryngeal attacks may be fatal, patients with laryngeal symptoms should administer FIRAZYR and immediately seek medical attention. The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials. These most frequently included redness and swelling. Other common adv
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
2. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
3. FDA Approves Fougeras Clotrimazole Cream USP 1%
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
8. FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
9. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
10. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
11. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix ... it has completed a collaborative research program ... analytics.  Using Fast Collective Evolution Technology (FACET), ... including all measurements obtained from each of ... Phase 2 clinical trials ASSERT, SUSTAIN and ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... 2015 Follow us on LinkedIn ... the fastest growing technologies in the life sciences industry. ... is driving growth in nucleic acid detection technologies like ... gene expressions will continue to benefit the qPCR and ... ranging from pharma, biotech, food & beverage to animal ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... LLC (L3I) has,successfully completed the Quality Management System (QMS) ... ISO 9001 and AS 9100,Certification under the rules of ... compliance and zero non-compliance issues. , ... Operations, Scott McAfee led,the creation, organization and refinement of ...
... Pharmaceuticals Inc.,is pleased to announce the appointment of Barry ... draw upon his 24 years of pharmaceutical sales and,marketing ... products for the company. , ... "We are extremely pleased to welcome Mr. ...
... 13 Johnston Blakely & Company, LLC, a,Boston-based ... that Michael,D. Webb has joined the firm as ... will,participate with the firm on internal and client-related ... equity placements, with a,particular focus on biopharmaceutical transactions. ...
Cached Biology Technology:Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification 2
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... headed by Dr. Sara Melville at the University of ... African sleeping sickness has evolved an unusual chromosomal structure ... parasite, the chromosomes are highly enriched in subtelomeric sequences ... to the gene-rich cores. These subtelomeres, in some ...
... the Pacific Northwest Research Institute (PNRI) and the National ... pattern of DNA damage in connective tissues in the ... stages of breast cancer and possibly serve as an ... In the United States, breast cancer is the second ...
... years, researchers have struggled to understand how IVIG worked. ... bean apparent contradiction. , Intravenous immunoglobulin (IVIG) is ... plasma that contains the pooled antibodies from thousands of ... assorted conditions; nonetheless, practitioners have used it off-label with ...
Cached Biology News:DNA to the defense 2Links between DNA damage and breast cancer studied 2A single sugar found responsible for an antibody's ability to treat inflammation 2A single sugar found responsible for an antibody's ability to treat inflammation 3
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Yersinia pestis...
Insect Cell Lysis Buffer 50 ml...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Biology Products: